Empowered Patient podcast

1
Nursing Informatics Improving Patient Care Reducing Clinician Burnout with Ali Morin symplr TRANSCRIPT

3 dagen geleden

—

Ali Morin, Chief Nursing Informatics Officer at symplr, emphasizes the need to focus on the challenges nurses face and AI's potential to reduce administrative burdens and nurse burnout. Significant staffing shortages, scheduling challenges, and increased patient acuity demand better data analytics and technology implementation to allow nurses to spend more time with patients and improve patient care. For successful integration of technology solutions into the nurses' workflow, pilot tests, training of new and experienced nurses, and listening to their concerns and ideas are essential. Ali explains, "We focus on the nursing informatics side -- that middle communicator between technology and the nurses at the bedside. So, I consider myself a translator. I listen to the clinicians and the nurses who are using our software, and we have a number of solutions that are applicable for direct care nurses as well as nurse managers and nurse leaders. I take in the pain points that they're experiencing today and bring them to our developers and our product teams. This allows them to understand the pain points that nurses are experiencing and how we can help solve some of those problems." "However, we're taking it to the next level and putting in some additional machine learning around which nurses are still available to pick up shifts and which nurses are still available who haven't maybe met their core component. Today, how that's done: there are spreadsheets, call lists, and post-it notes all over the place. Who have I called? Who have I checked with? Who hasn't seen this manual kind of back-and-forth? And so our work is really to make that balancing phase of the nursing scheduling simpler, pun intended, 100%, but also simpler so that we can make it so those nurses and nurse managers, the nurses can say, I want to work these kinds of shifts. The nurse managers can say, great, plug them in, and off they go. And then it's less time in that kind of back and forth between them." #symplr #Nurses #HealthTech #HealthcareAI #CompassSurvey symplr.com Listen to the podcast here…

1
Nursing Informatics Improving Patient Care Reducing Clinician Burnout with Ali Morin symplr 19:46

3 dagen geleden19:46

19:46

Ali Morin, Chief Nursing Informatics Officer at symplr, emphasizes the need to focus on the challenges nurses face and AI's potential to reduce administrative burdens and nurse burnout. Significant staffing shortages, scheduling challenges, and increased patient acuity demand better data analytics and technology implementation to allow nurses to spend more time with patients and improve patient care. For successful integration of technology solutions into the nurses' workflow, pilot tests, training of new and experienced nurses, and listening to their concerns and ideas are essential. Ali explains, "We focus on the nursing informatics side -- that middle communicator between technology and the nurses at the bedside. So, I consider myself a translator. I listen to the clinicians and the nurses who are using our software, and we have a number of solutions that are applicable for direct care nurses as well as nurse managers and nurse leaders. I take in the pain points that they're experiencing today and bring them to our developers and our product teams. This allows them to understand the pain points that nurses are experiencing and how we can help solve some of those problems." "However, we're taking it to the next level and putting in some additional machine learning around which nurses are still available to pick up shifts and which nurses are still available who haven't maybe met their core component. Today, how that's done: there are spreadsheets, call lists, and post-it notes all over the place. Who have I called? Who have I checked with? Who hasn't seen this manual kind of back-and-forth? And so our work is really to make that balancing phase of the nursing scheduling simpler, pun intended, 100%, but also simpler so that we can make it so those nurses and nurse managers, the nurses can say, I want to work these kinds of shifts. The nurse managers can say, great, plug them in, and off they go. And then it's less time in that kind of back and forth between them." #symplr #Nurses #HealthTech #HealthcareAI #CompassSurvey symplr.com Download the transcript here…

1
Mobile Vision Clinics Bringing Screening and Glasses to Children and Underserved Populations with Maggie Cline EyeCare4Kids TRANSCRIPT

4 dagen geleden

—

Maggie Cline, Executive Director at EyeCare4Kids Utah, highlights the importance of providing eye exams and eyeglasses to underserved children, their parents, and those in shelters, refugee camps, and Native American reservations. Early testing and glasses with the correct prescription can significantly impact academic performance, confidence, and social skills. Making wearing glasses cool and offering a wide selection of frames is key to encouraging everyone to wear them proudly. The EyeCare4Kids partners with various organizations to operate brick-and-mortar and mobile clinics in Utah, Nevada, Arizona, Idaho, and Africa with expansion plans. Maggie explains, "I think glasses are cool these days, but the kids have to wear their glasses. So something that we do, and I love that we do this, we don't just give them a selection of five or six glasses. They get hundreds to choose from because we know that if they feel good about what they're wearing, they will wear them. And so I just got a message from a nurse the other day telling me she has been so happy seeing these students proudly wearing their glasses. They absolutely love them, and they show them off. They tell their friends about them." "There are a lot of barriers. There are parents who are working, and in many of the homes just here in the US, both parents are working, so there's just no time. They don't want to take them out of school. I think there's just a lot of different reasons. I think there needs to be more education for parents to be able to notice the signs. Maybe kids have behavioral problems in the classroom that are often misdiagnosed. A kid sitting at the back of the classroom who isn't able to see the PowerPoint or the board is probably just unable to focus because they can't see clearly." "For example, our team was dispensed at an elementary school. There was a first grader who put on his pair of glasses, his first pair of glasses, and he had a significant prescription, and there was a brick wall right next to him. He was just amazed at the brick wall and that it had texture, and he just kept feeling it and talking about it. Then he looked at the school staff and was like, I can see your face. And they were just so amazed at the different details he could see." #ChildrensVisionCare #PediatricVisionCare #Glasses4Kids #EyeGlasses EyeCare4Kids.org Listen to the podcast here…

1
Mobile Vision Clinics Bringing Screening and Glasses to Children and Underserved Populations with Maggie Cline EyeCare4Kids 17:57

4 dagen geleden17:57

17:57

Maggie Cline, Executive Director at EyeCare4Kids Utah, highlights the importance of providing eye exams and eyeglasses to underserved children, their parents, and those in shelters, refugee camps, and Native American reservations. Early testing and glasses with the correct prescription can significantly impact academic performance, confidence, and social skills. Making wearing glasses cool and offering a wide selection of frames is key to encouraging everyone to wear them proudly. The EyeCare4Kids partners with various organizations to operate brick-and-mortar and mobile clinics in Utah, Nevada, Arizona, Idaho, and Africa with expansion plans. Maggie explains, "I think glasses are cool these days, but the kids have to wear their glasses. So something that we do, and I love that we do this, we don't just give them a selection of five or six glasses. They get hundreds to choose from because we know that if they feel good about what they're wearing, they will wear them. And so I just got a message from a nurse the other day telling me she has been so happy seeing these students proudly wearing their glasses. They absolutely love them, and they show them off. They tell their friends about them." "There are a lot of barriers. There are parents who are working, and in many of the homes just here in the US, both parents are working, so there's just no time. They don't want to take them out of school. I think there's just a lot of different reasons. I think there needs to be more education for parents to be able to notice the signs. Maybe kids have behavioral problems in the classroom that are often misdiagnosed. A kid sitting at the back of the classroom who isn't able to see the PowerPoint or the board is probably just unable to focus because they can't see clearly." "For example, our team was dispensed at an elementary school. There was a first grader who put on his pair of glasses, his first pair of glasses, and he had a significant prescription, and there was a brick wall right next to him. He was just amazed at the brick wall and that it had texture, and he just kept feeling it and talking about it. Then he looked at the school staff and was like, I can see your face. And they were just so amazed at the different details he could see." #ChildrensVisionCare #PediatricVisionCare #Glasses4Kids #EyeGlasses EyeCare4Kids.org Download the transcript here…

1
Customized Allograft and Xenograft Biomaterials for Use in Regenerative Medicine with Olivier Visa Evergen TRANSCRIPT

5 dagen geleden

—

Olivier Visa, President and CEO of Evergen specializes in developing and manufacturing biomaterials for use in regenerative medicine. These customized biomaterial solutions use xenografts, allografts, and emerging technologies inside and outside the body with applications in wound healing, cardiac, dental, breast, neuro, and spine repair. This approach provides surgeons with a broader range of biomaterials to better tailor treatments for individual patients. Olivier explains, "There is a multitude that we can support. There is form and function, and I can give you a couple of examples of biomaterials in regenerative medicine. One is bovine pericardium, which is bovine collagen that we use for the development and manufacturing of cardiac heart valves. Another one would be acellular dermal matrix from human tissue that we use for reconstruction in plastic and, of course, with surgeries such as breast reconstruction after mastectomy." "Think about the body as a whole, and I'll give you a couple of examples where- when you're in cardiac - whether it's a patch or a valve, we're inside the body. When we're in breast reconstruction, we are totally inside the body. When we're in the neuro spine, we're totally inside the body, whether you're repairing or restoring or regenerating peripheral nerves or dura around the brain, you're inside the body. And yes, you are right, wound management is part of it, whether it's diabetic food, ulcer, ulcer or some form of a burn, then I would say you're looking at the skin as an organ and repairing, restoring, and regenerating that skin." #Evergen #TissueEngineering #RegenerativeMedicine #CDMO #Biomaterials #Biotechnology #LifeSciences #MedicalDevices #SportsMedicine #Orthopedics #Surgeons evergenbio.com Listen to the podcast here…

1
Customized Allograft and Xenograft Biomaterials for Use in Regenerative Medicine with Olivier Visa Evergen 20:16

5 dagen geleden20:16

20:16

Olivier Visa, President and CEO of Evergen specializes in developing and manufacturing biomaterials for use in regenerative medicine. These customized biomaterial solutions use xenografts, allografts, and emerging technologies inside and outside the body with applications in wound healing, cardiac, dental, breast, neuro, and spine repair. This approach provides surgeons with a broader range of biomaterials to better tailor treatments for individual patients. Olivier explains, "There is a multitude that we can support. There is form and function, and I can give you a couple of examples of biomaterials in regenerative medicine. One is bovine pericardium, which is bovine collagen that we use for the development and manufacturing of cardiac heart valves. Another one would be acellular dermal matrix from human tissue that we use for reconstruction in plastic and, of course, with surgeries such as breast reconstruction after mastectomy." "Think about the body as a whole, and I'll give you a couple of examples where- when you're in cardiac - whether it's a patch or a valve, we're inside the body. When we're in breast reconstruction, we are totally inside the body. When we're in the neuro spine, we're totally inside the body, whether you're repairing or restoring or regenerating peripheral nerves or dura around the brain, you're inside the body. And yes, you are right, wound management is part of it, whether it's diabetic food, ulcer, ulcer or some form of a burn, then I would say you're looking at the skin as an organ and repairing, restoring, and regenerating that skin." #Evergen #TissueEngineering #RegenerativeMedicine #CDMO #Biomaterials #Biotechnology #LifeSciences #MedicalDevices #SportsMedicine #Orthopedics #Surgeons evergenbio.com Download the transcript here…

1
Personalized Tech-Enabled Weight Care Includes Medications and Lifestyle Intervention with Dr. Rekha Kumar Found TRANSCRIPT

6 dagen geleden

—

Dr. Rekha Kumar, Chief Medical Officer at Found, is focused on weight care, not just weight management, to provide personalized medical care. GLP-1 medications have changed the landscape of obesity treatment, providing doctors with more effective tools for patients, but they don't work for everyone. With this telehealth approach, patients engage with the platform to determine a tailored treatment plan based on each patient's unique biology, lifestyle, and history. There is also an increased stigma around obesity due to the availability of GLP-1s, reinforcing the need for new medications and approaches based on real-world outcomes. Rekha explains, "I would say the way GLP-1s have changed this entire field of medicine is that doctors now feel like they have a tool that works that they can offer their patients. Although GLP-1s don't work perfectly in everybody, and there may be people who don't respond well to them for decades or longer than decades, doctors felt like all they could tell patients was to eat less and exercise more. Even when doctors said that, I think they felt like what they were offering wasn't very useful. Now, an actual tool, or a class of medicine, can be very effective for patients." "I am looped into the conversation on stigma. In some ways, it’s been helpful to that conversation in the sense that people like Oprah have come out and said that now she realizes biology is involved in body weight control and that thin people are wired differently. They don't have as much of a preoccupation with food or noise." "In some ways, it's reduced the stigma by bringing attention to the role of biology and hormones that contribute to our body weight that we don't have control of. Unfortunately, now that there is this tool that's so powerful, some would say that it's made weight stigma worse because if somebody chooses not to take this medicine, they're judged for not wanting to be thin." #JoinFound #WeightCare #WeightManagment #Obesity #GLP1 joinfound.com Listen to the podcast here…

1
Personalized Tech-Enabled Weight Care Includes Medications and Lifestyle Intervention with Dr. Rekha Kumar Found 20:10

6 dagen geleden20:10

20:10

Dr. Rekha Kumar, Chief Medical Officer at Found, is focused on weight care, not just weight management, to provide personalized medical care. GLP-1 medications have changed the landscape of obesity treatment, providing doctors with more effective tools for patients, but they don't work for everyone. With this telehealth approach, patients engage with the platform to determine a tailored treatment plan based on each patient's unique biology, lifestyle, and history. There is also an increased stigma around obesity due to the availability of GLP-1s, reinforcing the need for new medications and approaches based on real-world outcomes. Rekha explains, "I would say the way GLP-1s have changed this entire field of medicine is that doctors now feel like they have a tool that works that they can offer their patients. Although GLP-1s don't work perfectly in everybody, and there may be people who don't respond well to them for decades or longer than decades, doctors felt like all they could tell patients was to eat less and exercise more. Even when doctors said that, I think they felt like what they were offering wasn't very useful. Now, an actual tool, or a class of medicine, can be very effective for patients." "I am looped into the conversation on stigma. In some ways, it’s been helpful to that conversation in the sense that people like Oprah have come out and said that now she realizes biology is involved in body weight control and that thin people are wired differently. They don't have as much of a preoccupation with food or noise." "In some ways, it's reduced the stigma by bringing attention to the role of biology and hormones that contribute to our body weight that we don't have control of. Unfortunately, now that there is this tool that's so powerful, some would say that it's made weight stigma worse because if somebody chooses not to take this medicine, they're judged for not wanting to be thin." #JoinFound #WeightCare #WeightManagment #Obesity #GLP1 joinfound.com Download the transcript here…

1
Nanoscale Polishing of Scalpel Blades Removes Jagged Edges Reduces Hypertrophic Scarring with Tim Tobin Planatome TRANSCRIPT

9 dagen geleden

—

Tim Tobin, CEO and Founder of Planatome, has a background in the semiconductor industry where precision polishing techniques were developed. Planatome has used that technology to create molecularly smooth scalpel blades that remove all the jagged edges on traditional surgical scalpels. These new nano polished blades significantly reduce scarring and inflammation from incisions and improve healing outcomes for patients, especially those with darker skin tones who are more prone to hypertrophic scarring. The challenge is disrupting an industry that has not changed in over 100 years and that has been driven by reducing the costs, not improving the blade. Tim explains, "So we picked the surgical scalpel because it's still the foundation, the primary incision tool, whether it's a minimally invasive procedure or a procedure with a lot of cutting. So we started with that. We've since applied our technology to many other surgical instruments. We started with the scalpel, which was patented in 1915. There's been no change, no technological change, just change to drag down the cost. So it's just completely commoditized, a scalpel blade somewhere in the 20 to 50 cent range, and nobody thinks about it because everybody just uses a scalpel, and they don't need to be more critical." "So we started looking, and if you look at a scalpel blade underneath magnification, it looks almost like it's highly serrated and jagged because they're made by taking a piece of stainless steel, and they grind it up to a point, and that's the cutting edge. But they leave it like that." "We took that, and we said, okay, well, what if we polish it and take out all of those jagged serrations, at least a thousand times smoother. Now if you measure the surface, it changes the cutting mechanism from tearing and snagging to a nice clean incision. So some of the challenges in that is when surgeons have been using the same thing pretty much their whole career, when they try something different, that's not always something they want to think about." #Planatome #MedTech #MedicalDevice #Surgery planatome.com Listen to the podcast here…

1
Nanoscale Polishing of Scalpel Blades Removes Jagged Edges Reduces Hypertrophic Scarring with Tim Tobin Planatome 18:25

9 dagen geleden18:25

18:25

Tim Tobin, CEO and Founder of Planatome, has a background in the semiconductor industry where precision polishing techniques were developed. Planatome has used that technology to create molecularly smooth scalpel blades that remove all the jagged edges on traditional surgical scalpels. These new nano polished blades significantly reduce scarring and inflammation from incisions and improve healing outcomes for patients, especially those with darker skin tones who are more prone to hypertrophic scarring. The challenge is disrupting an industry that has not changed in over 100 years and that has been driven by reducing the costs, not improving the blade. Tim explains, "So we picked the surgical scalpel because it's still the foundation, the primary incision tool, whether it's a minimally invasive procedure or a procedure with a lot of cutting. So we started with that. We've since applied our technology to many other surgical instruments. We started with the scalpel, which was patented in 1915. There's been no change, no technological change, just change to drag down the cost. So it's just completely commoditized, a scalpel blade somewhere in the 20 to 50 cent range, and nobody thinks about it because everybody just uses a scalpel, and they don't need to be more critical." "So we started looking, and if you look at a scalpel blade underneath magnification, it looks almost like it's highly serrated and jagged because they're made by taking a piece of stainless steel, and they grind it up to a point, and that's the cutting edge. But they leave it like that." "We took that, and we said, okay, well, what if we polish it and take out all of those jagged serrations, at least a thousand times smoother. Now if you measure the surface, it changes the cutting mechanism from tearing and snagging to a nice clean incision. So some of the challenges in that is when surgeons have been using the same thing pretty much their whole career, when they try something different, that's not always something they want to think about." #Planatome #MedTech #MedicalDevice #Surgery planatome.com Download the transcript here…

1
Tackling Rare Autoimmune Diseases with Novel Bispecific Antibodies with Kiran Nistala Zura Bio TRANSCRIPT

10 dagen geleden

—

Kiran Nistala, Chief Medical Officer and head of development at Zura Bio, describes how their novel molecules target multiple pathways to provide more effective treatments for patients with autoimmune diseases. This is particularly necessary for those with complex, heterogeneous manifestations not well addressed by current therapies. Zura Bio's novel molecules target rare diseases such as systemic sclerosis and hidradenitis suppurativa and show potential for use in combination with existing approaches. Kiran, "Developing bispecifics is a known, but it's quite a technical skill, and I think there are lots of reasons—first, bioengineering to get the right molecule. Secondly, you must also know how to design studies to show that both sides are doing what you expect of that molecule. So both pathways are being affected. And I guess you must also choose the right disease where you think those pathways are super important. So, we've been incredibly thoughtful in our approach- we haven't just jumped in, and some of that time we've taken is really to speak to patients and physicians and learn and hopefully overcome some of the mistakes we've seen from other competitors." "Your point about heterogeneity speaks to why we're stuck and don't have enough medicines that are changing the boundaries. If I give you a specific example, scleroderma, I talked a bit about it. One of the points is that there's no treatment for the whole of this disease -there's just treatment for the lung. And maybe the lungs are a bit simpler, but what you want to treat is every organ, the whole of disease. That issue is probably more varied between patients. The same is true for our second disease of interest: hidradenitis suppurativa. There's been some great progress, and molecules are out there now that are licensed to treat it. But unfortunately, the same thing occurs. So, more than half of patients in recent studies are still not getting good or very good responses. I think it's not just one thing, but heterogeneity certainly contributes to it." #ZuraBio #SystemicSclerosis #SSc #Scleroderma #HidradenitisSuppurativa #Autoimmune #Immunology #RareDisease #Biologic zurabio.com Listen to the podcast here…

1
Tackling Rare Autoimmune Diseases with Novel Bispecific Antibodies with Kiran Nistala Zura Bio 18:22

10 dagen geleden18:22

18:22

Kiran Nistala, Chief Medical Officer and head of development at Zura Bio, describes how their novel molecules target multiple pathways to provide more effective treatments for patients with autoimmune diseases. This is particularly necessary for those with complex, heterogeneous manifestations not well addressed by current therapies. Zura Bio's novel molecules target rare diseases such as systemic sclerosis and hidradenitis suppurativa and show potential for use in combination with existing approaches. Kiran, "Developing bispecifics is a known, but it's quite a technical skill, and I think there are lots of reasons—first, bioengineering to get the right molecule. Secondly, you must also know how to design studies to show that both sides are doing what you expect of that molecule. So both pathways are being affected. And I guess you must also choose the right disease where you think those pathways are super important. So, we've been incredibly thoughtful in our approach- we haven't just jumped in, and some of that time we've taken is really to speak to patients and physicians and learn and hopefully overcome some of the mistakes we've seen from other competitors." "Your point about heterogeneity speaks to why we're stuck and don't have enough medicines that are changing the boundaries. If I give you a specific example, scleroderma, I talked a bit about it. One of the points is that there's no treatment for the whole of this disease -there's just treatment for the lung. And maybe the lungs are a bit simpler, but what you want to treat is every organ, the whole of disease. That issue is probably more varied between patients. The same is true for our second disease of interest: hidradenitis suppurativa. There's been some great progress, and molecules are out there now that are licensed to treat it. But unfortunately, the same thing occurs. So, more than half of patients in recent studies are still not getting good or very good responses. I think it's not just one thing, but heterogeneity certainly contributes to it." #ZuraBio #SystemicSclerosis #SSc #Scleroderma #HidradenitisSuppurativa #Autoimmune #Immunology #RareDisease #Biologic zurabio.com Download the transcript here…

1
New Generation ADC Therapy Demonstrates High Response Rates in Neuroendocrine Tumors with Dr. Rafael Amado Zai Lab TRANSCRIPT

11 dagen geleden

—

Dr. Rafael Amado, President, Head of Global Research and Development at Zai Lab, highlights the renewed interest in antibody-drug conjugates (ADCs) with advancements in linker technology and payload delivery, leading to improved therapeutic windows and reduced side effects. The Zai Lab lead ADC ZL-1310 has shown promising results in small cell lung cancer and the ability to cross the blood-brain barrier to treat brain metastases, a common complication in small cell lung cancer. Combining ADCs with immunotherapy can potentially enhance the immune response. Rafael elaborates, "ADCs have undergone a bit of a renaissance. In the past, traditional ADCs had many drawbacks. They had what's called a narrow therapeutic window. So the dose that was effective was very close to the dose that was toxic. This was due to many factors. The construction of the antibodies and the chemotherapy, which we call payload, wasn't liberated in the right compartment. Either the tumor microenvironment or the antibody was not well internalized and didn't go into the cancer cell." "There are now new generations of antibody-drug conjugates, and ZL-1310 is one of them. It uses a technology called TMALIN. The advantage of this is that the linker is quite specific and the antibody internalizes, it can release the payload, which is a different chemotherapy, than a classic ADC. Also, it can be digested in the tumor microenvironment, and the chemotherapy can penetrate cells that don't have the target just by influx into the cell. So that's called the bystander effect." #ZaiLaboratory #innovation #Cancer #ADC #Antibodydrug #Biotech #ClinicalTrials #DrugDevelopment #LifeSciences #Healthcare zailaboratory.com Listen to the podcast here…

1
New Generation ADC Therapy Demonstrates High Response Rates in Neuroendocrine Tumors with Dr. Rafael Amado Zai Lab 20:58

11 dagen geleden20:58

20:58

Dr. Rafael Amado, President, Head of Global Research and Development at Zai Lab, highlights the renewed interest in antibody-drug conjugates (ADCs) with advancements in linker technology and payload delivery, leading to improved therapeutic windows and reduced side effects. The Zai Lab lead ADC ZL-1310 has shown promising results in small cell lung cancer and the ability to cross the blood-brain barrier to treat brain metastases, a common complication in small cell lung cancer. Combining ADCs with immunotherapy can potentially enhance the immune response. Rafael elaborates, "ADCs have undergone a bit of a renaissance. In the past, traditional ADCs had many drawbacks. They had what's called a narrow therapeutic window. So the dose that was effective was very close to the dose that was toxic. This was due to many factors. The construction of the antibodies and the chemotherapy, which we call payload, wasn't liberated in the right compartment. Either the tumor microenvironment or the antibody was not well internalized and didn't go into the cancer cell." "There are now new generations of antibody-drug conjugates, and ZL-1310 is one of them. It uses a technology called TMALIN. The advantage of this is that the linker is quite specific and the antibody internalizes, it can release the payload, which is a different chemotherapy, than a classic ADC. Also, it can be digested in the tumor microenvironment, and the chemotherapy can penetrate cells that don't have the target just by influx into the cell. So that's called the bystander effect." #ZaiLaboratory #innovation #Cancer #ADC #Antibodydrug #Biotech #ClinicalTrials #DrugDevelopment #LifeSciences #Healthcare zailaboratory.com Download the transcript here…

1
Effectively Diagnosing and Treating Traumatic Brain Injuries with Dr. Halinder Mangat Brain Trauma Foundation TRANSCRIPT

12 dagen geleden

—

Dr. Halinder Mangat, Director of Research at the Brain Trauma Foundation, has developed evidence-based guidelines for treating severe traumatic brain injuries, which have been shown to improve outcomes significantly. The Foundation is conducting research in collaboration with the US Defense Department and Veterans Administration, including a clinical trial on the use of lumbar drainage to reduce intracranial pressure from a brain injury. While the brain was once thought incapable of healing, research shows early intervention from injuries can result in the regeneration of cells and formation of new neural circuits. Halinder explains, "The initial focus of the Brain Trauma Foundation's mission was treatment. The Brain Trauma Foundation in 1997 became the first surgical organization and first professional body to produce evidence-based guidelines for the treatment of severe head injury. That means looking at the comprehensive literature body, finding out what robust research is, and compiling it all. Some studies may have contradictory results. We compile it all in a very objective, systematic way to then frame recommendations as to the best practice, and these fall under the umbrella of evidence-based medicine. In 1997, the first edition was published. Over the years, multiple studies have shown that this set of guidelines has improved good outcomes or decreased poor outcomes by 50%, which is the most remarkable intervention, perhaps short of vaccines or antibiotics. But in the surgical field, it is probably the most impactful intervention." "So the first impact of the injury causes X amount of damage, and then following that, there is a cascade of it like dominoes falling. The whole focus has been to prevent downstream dominoes from falling by early intervention. And after the first injury when a few dominoes, for example, have fallen, the goal of the guidelines has been to as early and as intensively as possible to minimize downstream dominos falling, which means secondary injury, which in itself has its own legacy of influencing outcome. Over a period of time, there's been a lot of trials to try neuroprotective drugs, which would, in the first instance, mitigate the secondary injury." #BrainTraumaFoundation #BTF #Neurology #Neurologist #TraumaticBrainInjury #TBI #BrainTrauma braintrauma.org Listen to the podcast here…

everydrop by Whirlpool Ice and Water Refrigerator Filter 1, EDR1RXD1, Single-Pack , Purple

TurboTax Deluxe 2024 Tax Software, Federal & State Tax Return [PC/MAC Download]

Amazon Basics Multipurpose Copy Printer Paper, 8.5 x 11 inches, 20 lb, 1 Ream, 500 Sheets, 92 Bright, White

Podcasts die het beluisteren waard zijn

Empowered Patient Podcast

Empowered Patient Podcast

Podcasts die het beluisteren waard zijn

Welkom op Player FM!

Ailun 3 Pack Screen Protector for iPhone 16 Pro Max [6.9 inch] + 3 Pack Camera Lens Protector with Installation Frame,Sensor Protection,Dynamic Island Compatible,Case Friendly Tempered Glass Film

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

Tubi: Watch Free Movies & TV Shows

Minecraft

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

Korte handleiding